Lakefront Biotherapeutics (GLPGF) EPS (Diluted) (QoQ) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EPS (Diluted) (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.59 Bn | 197.60 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.18 Bn | 178.00 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.46 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.66 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.95 Bn | 30.64 Bn | 992.69 Mn |
| 8 | Biogen | 31.27 Bn | 29.98 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.82 Bn | 29.82 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -395.78% |
| Mar 31, 2026 | -100.00% |
| Dec 31, 2025 | 64,296.40% |
| Sep 30, 2025 | -430.79% |
| Jun 30, 2025 | 209.16% |
| Mar 31, 2025 | -100.20% |
| Dec 31, 2024 | 74,463.73% |
| Sep 30, 2024 | -285.82% |
| Jun 30, 2024 | -41.55% |
| Mar 31, 2024 | -99.96% |
| Dec 31, 2023 | 642,702.41% |
| Sep 30, 2023 | -5,681.25% |
| Jun 30, 2023 | -97.46% |
| Mar 31, 2023 | -89.33% |
| Dec 31, 2022 | 2,046.92% |
| Sep 30, 2022 | 207.04% |
| Jun 30, 2022 | -35.92% |
| Mar 31, 2022 | 76.24% |
| Dec 31, 2021 | 82.16% |
| Sep 30, 2021 | -134.12% |